| abstract |
The present invention relates to compounds of formula (1.0.0) and pharmaceutically acceptable salts thereof, wherein the substituents have the following meanings: j is 0 or 1; with the proviso that if j is 0 then n must be 2; k is 0 or 1, m is 1, 2 or 3; n is 1 or 2; W1 and W2 are independently -O-; -S (= O) t -, wherein t is 0, 1 or 2; or -N (R 3); Y is = C (R 1a) -; or - [N (O) k] - wherein k is 0 or 1; RA and RB are -H; -F; -CF3; alkyl it; optionally substituted cycloalkyl; phenyl or benzyl; or RA and RB together form a spiro moiety; RC and RD have the same meaning as given above for RA and RB, except that one of them must be hydrogen; R1 and R2 are independently -H; -F; -Cl; -CN; -NO 2; alkyl; alkynyl; fluorinated alkyl; -OR16; or -C (= O) NR 22a R 22b; R3 is hydrogen; phenyl; benzyl; or -OR 16; R4, R5 and R6 are independently selected from the group consisting of -H; -F; -Cl; alkynyl; -R 16; -OR16; -S (= O) pR16; -C (= O) R16; -C (= O) OR 16; -OC (= O) R16; -CN; Optionally substituted alkyl or alkoxy; an aryl or heterocyclic moiety; or R5 and R6 are taken together to form a group; J1 is a saturated or unsaturated monocyclic or fused polycyclic system optionally containing heteroatom (s); J2 is a saturated or unsaturated monocyclic or fused polycyclic system optionally containing heteroatom (s); D is independently selected from the group consisting of phosphoric acid, phosphinic acid, phosphonic acid, alkylphosphono, alkylphosphinyl, phosphoramido; a group derived from sulfuric acid, sulfonic acid; sulfonamido or acylsulfonamido. The invention also relates to compounds of formula (1.0.0) for use in the treatment of a PDE4 isozyme-mediated disease or condition, and to pharmaceutical compositions containing them. SHE |